Maxine Gowen

Maxine Gowen was the founder of Trevena, Inc., founded in 2007, and served as Director from 2018 to 2021.
Current jobs include Chairman at Passage Bio, Inc. since 2022, Director at Conforma Therapeutics Corp., Independent Director at Aclaris Therapeutics, Inc. since 2019, and Director at TamuroBio, Inc. since 2021.
Former jobs include Independent Director at Human Genome Sciences, Inc. from 2011 to 2012; Director roles at Morphotek, Inc., Santarus, Inc., and Azelon Pharmaceuticals, Inc.; Director at Biotechnology Innovation Organization from 2008 to 2018; Independent Director at Akebia Therapeutics, Inc. from 2014 to 2021; Director at Panorama Medicine, Inc. from 2020 to 2021; Independent Director at Aceragen, Inc. from 2016 to 2023; Independent Director at Idera Pharmaceuticals, Inc. from 2016 to 2022; Director at Life Sciences Pennsylvania from 2016 to 2021; Independent Non-Executive Director at Merus NV from 2021 to 2025; President & Managing Partner at GSK Equity Investments Ltd. from 2002 to 2005; SVP-External Drug Discovery Excellence Center at GSK Plc from 2005 to 2007; VP-Drug Discovery & Musculoskeletal Diseases at GSK Plc from 1992 to 2002; Head-Bone Cell Biology Group at the University of Bath from 1989 to 1992; and Senior Vice President at Center of Excellence For External Drug Discovery.
Education includes a doctorate from the University of Bath, an undergraduate degree from the University of Bristol in 1979, a doctorate from The University of Sheffield in 1984, and an MBA from The Wharton School of the University of Pennsylvania in 2002.